Meetings

Schedule and Program for the 2018 ASH Summit on Emerging Immunotherapies

The following programming corresponds to the 2018 ASH Summit on Emerging Immunotherapies for Hematologic Diseases.

Thursday - July 12

8:00 a.m. – 7:00 p.m.	Registration
8:00 a.m. – 8:45 a.m.	Breakfast and Exhibits
8:45 a.m. – 9:05 a.m.	Welcome, Introduction, and Announcements Program Co-Chairs: Catherine M. Bollard, MD, Children's National Medical Center Rodrigo T. Calado, MD, PhD, University of São Paulo Sergio A. Giralt, MD, Memorial Sloan Kettering Cancer Center Jeffrey S. Miller, MD, University of Minnesota ASH Task Force on Immunotherapies Co-Chairs: Sophie Paczesny, MD, Indiana University School of Medicine Steven Pavletic, MD, National Cancer Institute, National Institutes of Health
9:05 a.m. – 11:05 a.m.	Cellular Therapies and Their Role in the Treatment of Malignant and Non-Malignant Hematologic Disease Chair: Jeffrey S. Miller, MD, University of Minnesota Speakers: Stanley R. Riddell, MD, Fred Hutchinson Cancer Research Center Strategies to Improve Safety and Efficacy of CAR T Cells in Hematologic Malignancies Helen E. Heslop, MD, DSc, Baylor College of Medicine Antigen Specific T-Cell Therapy Jeffrey S. Miller, MD, University of Minnesota Natural Killer Cells to Treat or Prevent Cancer Relapse Bruce R. Blazar, MD, University of Minnesota Immune Regulatory Cell Therapies for Graft-Versus-Host Disease
11:05 a.m. – 11:35 a.m.	Panel Discussion Moderator: Jeffrey S. Miller, MD, University of Minnesota
11:35 a.m. – 12:35 p.m.	Lunch
12:35 p.m. – 2:35 p.m.	Engineered and Non-Engineered T Cells as Tools for Immunotherapy: Beyond CAR T Cells Chair: Catherine M. Bollard, MD, Children's National Medical Center Speakers: Stephen M. Ansell, MD, PhD, Mayo Clinic Checkpoint Inhibitors in Lymphoma Stephen Gottschalk, MD, St. Jude Children's Research Hospital BiTEs, DARTs, and Other Bispecifics Ronald Levy, MD, Stanford University Combining Intratumoral Injections of TLR Agonists With Checkpoint Antibodies Danielle Townsley, MD, AZ MedImmune Augmenting the Efficacy of Immunotherapy for Aplastic Anemia
2:35 p.m. – 3:05 p.m.	Panel Discussion Moderator: Catherine M. Bollard, MD, Children's National Medical Center
3:05 p.m. – 3:20 p.m.	Networking Coffee Break
3:20 p.m. – 4:20 p.m.	Company Presentations
4:20 p.m. – 6:20 p.m.	Effective Clinical Trial Design in the Field of Immunotherapy Chair: Sergio A. Giralt, MD, Memorial Sloan Kettering Cancer Center Speakers: James Kochenderfer, MD, National Cancer Institute, National Institutes of Health Chimeric Antigen Receptor T Cells: The Balance Between Efficacy and Toxicity Marcelo C. Pasquini, MD, Medical College of Wisconsin Developing Cell Therapies in a Cooperative Group Setting Alexander M. Lesokhin, MD, Memorial Sloan Kettering Cancer Center Checkpoint Blockade in Myeloma, is there a Path Forward? Yogen Saunthararajah, MD, Cleveland Clinic Immunotherapies for Myelodysplastic Syndromes: To Modulate or Augment?
6:20 p.m. – 6:50 p.m.	Panel Discussion Moderator: Sergio A. Giralt, MD, Memorial Sloan Kettering Cancer Center
7:00 p.m. – 8:30 p.m.	Welcome and Networking Reception

Friday - July 13

8:00 a.m. – 4:00 p.m.	Registration
8:00 a.m. – 9:00 a.m.	Breakfast and Exhibits
9:00 a.m. – 9:20 a.m.	Opening Remarks Program Co-Chairs: Catherine M. Bollard, MD, Children's National Medical Center Rodrigo T. Calado, MD, PhD, University of São Paulo Sergio A. Giralt, MD, Memorial Sloan Kettering Cancer Center Jeffrey S. Miller, MD, University of Minnesota
9:20 a.m. – 10:35 a.m.	Breakout Sessions Breakout I: Preparing the Garage: How to Prepare for the Commercialization of CAR T Cells Moderator: Catherine M. Bollard, MD, Children's National Medical Center Speakers: Adrian Gee, PhD, Baylor College of Medicine GMP Requirements for CAR T Cells Kristin Baird, MD, U.S. Food and Drug Administration Regulatory Considerations for Gene Modified T-Cell Therapy Fabio Fachin, PhD, Torque Therapeutics, and Boro Dropulić, PhD, MBA, Lentigen Technology Automation and Decentralization of CAR T Cell Manufacture Breakout II: Toxicity Management: Can We Make This Easier? Moderator: Sergio A. Giralt, MD, Memorial Sloan Kettering Cancer Center Speakers: Jennifer Holter Chakrabarty, MD, University of Oklahoma The Development of Guidelines for Toxicity Management of Checkpoint Inhibitors: What Can We Learn? James Kochenderfer, MD, National Cancer Institute, National Institutes of Health Current Standards for Treatment and Prevention of Toxicities Related to CAR T-Cell Therapies Bianca Santomasso, MD, PhD, Memorial Sloan Kettering Cancer Center Neurotoxicity: Are There Vulnerable Populations: Very Old or Very Young? Leslie Kean, MD, PhD, Seattle Children's Research Institute Biomarkers and Toxicity
10:35 a.m. – 11:50 a.m.	Breakout Sessions Breakout III: The Challenge Beyond CAR T: What Does the Future Offer for Commercial Immunotherapies and Combinations? Moderator: Jeffrey S. Miller, MD, University of Minnesota Speakers: Stephen Gottschalk, MD, St. Jude Children's Research Hospital Immune Engagers Glenn Dranoff, MD, Novartis Immune Activators Stephen M. Ansell, MD, PhD, Mayo Clinic Immune Checkpoint Inhibitors in Lymphoma Marc Theoret, MD, U.S. Food and Drug Administration Combination Therapies Breakout IV: Beyond Cancer: Development of Novel Immunotherapies for Non-Malignant Hematologic Diseases Moderator: Rodrigo Calado, MD, PhD, University of São Paulo Speakers: Bruce R. Blazar, MD, University of Minnesota Development of Novel Immunotherapies for Non-Malignant Hematologic Diseases: An Academic Perspective Steven Pavletic, MD, National Cancer Institute, National Institutes of Health Federal Agency Perspective Aaron Foster, PhD, Bellicum Pharmaceuticals Industry Perspective Kathleen Weis, Aplastic Anemia and MDS International Foundation Patient Advocate Perspective
11:50 a.m. – 1:00 p.m.	Lunch
1:00 p.m. – 1:50 p.m.	Company Presentations
1:50 p.m. – 2:50 p.m.	Reports From Breakout Sessions
2:50 p.m. – 3:05 p.m.	Panel Discussion Moderators: Catherine M. Bollard, MD, Children's National Medical Center Rodrigo T. Calado, MD, PhD, University of São Paulo Sergio A. Giralt, MD, Memorial Sloan Kettering Cancer Center Jeffrey S. Miller, MD, University of Minnesota
3:05 p.m. – 3:50 p.m.	Closing Keynote Address Steven A. Rosenberg, MD, PhD, National Cancer Institute, National Institutes of Health Lymphocytes as a Drug for the Treatment of Patients With Cancer
3:50 p.m. – 4:10 p.m.	Closing Remarks From Program Co-Chairs